Ocular Therapeutix, Inc.
OCULHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeOcular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable. At a $1.96B market cap, Ocular Therapeutix, Inc. ranks as a small-cap company within healthcare. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.
Market Cap
$1.96B
Beta
0.88
P/E (TTM)
—
P/E (Fwd)
-5.83
EPS (TTM)
$-1.41
EPS (Fwd)
$-1.54
ROE
-68.5%
ROA
-32.9%
Cash
$666.7M
Total Debt
$79.5M
Free CF
-$148.8M
52W Change
-20.8%
Annual Financials
Cash vs Debt
With $666.7M in cash and $79.5M in debt, OCUL maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$148.8M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -68.5%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has been relatively flat, moving from $51.5M (2022) to $52.0M (2025).
With cash comfortably exceeding debt, OCUL has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing OCUL's risk profile alongside its fundamentals and technical indicators provides a more complete picture.